Navigation Links
Amylin Co-Founder Announces Plans to Vote for Eastbourne Slate
Date:5/11/2009

FRANKFORT, Mich., May 11 /PRNewswire/ -- The following is being released today by Howard E. Greene, Jr.

To my fellow shareholders:

As the founding CEO of Amylin and a board member for almost 22 years, I want you to know how I plan to vote at our annual meeting.

In my opinion Amylin's talented employee team has created one of the best product and technology platforms in the diabetes and obesity area. But, shareholders have suffered because sales results have not reflected the commercial potential of that platform.

I commend our present management team, under Dan Bradbury's leadership, for recognizing that they need to achieve a more effective working relationship with Lilly, and that they must design a more innovative strategy for convincing primary care physicians that Amylin's injectible medicines are their best treatment option for patients with diabetes.

Our board of directors will play a strategic role in meeting these challenges. I believe management will have more freedom to think outside of the box if we replace the directors most directly involved in crafting the disappointing commercialization strategy.

Also, with the departures of Ginger Graham and me, the Amylin board loses more than 60% of its stock ownership. I think our investors would be well served by adding directors who directly represent large shareholdings.

So, I have decided to vote for the slate proposed by Eastbourne, including the Icahn nominees.

Respectfully,

Howard E. Greene, Jr., Co-Founder of Amylin


'/>"/>
SOURCE Howard E. Greene, Jr.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
2. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
3. Amylin Pharmaceuticals Reports Third Quarter Financial Results
4. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
5. Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
6. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
7. Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
8. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amylin Pharmaceuticals to Webcast First Quarter Results
10. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
11. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... SAN DIEGO , Feb. 23, 2017 /PRNewswire/ ... protein research tools, announced the acquisition of GenWay ... with a comprehensive service and product offering for ... "This acquisition will facilitate growth and enhance capabilities ... proteins, antibodies, and ELISA assays will nicely complement ...
(Date:2/22/2017)... 2017  Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics ... biopharmaceutical products for companion animals, will host a live conference ... to discuss financial results from the fourth quarter and full ... and investors may access the audio webcast or ... ...
(Date:2/22/2017)... , Feb. 22, 2017  PrimeVax Immuno-Oncology, Inc. ... be presenting at the Annual Biocom Global Life Science ... 2, at 11:15 AM, at the Torrey Pines Lodge, ... to the organizers at Biocom who have chosen our ... symposium of biotechnology companies, investors, and clinical researchers," said ...
(Date:2/22/2017)... ON (PRWEB) , ... February 22, 2017 , ... ... on discovery and development of precision treatments for neurodegenerative diseases, today announced it ... validate the ProMIS approach.” This is one of a series of commentaries from ...
Breaking Biology Technology:
(Date:1/30/2017)... --  Invitae Corporation (NYSE: NVTA ), ... announced that it will report its fourth quarter and ... Monday, February 13, 2017, and Invitae,s management team will ... Eastern / 1:45 p.m. Pacific. During ... results, guidance, and recent developments and will spend the ...
(Date:1/24/2017)... , Jan. 24, 2017 Biopharm ... of the laboratory use of nuclear magnetic resonance ... experienced end-users and profiled current practices, developments, trends ... as well as growth and opportunities. These areas ... suppliers, NMR instruments, needs and innovation requirements, hyphenated ...
(Date:1/19/2017)... , January 19, 2017 According to a new ... and Forecast, 2014 - 2022," the global biometric sensor market is expected to ... to 2022. In 2015, Asia-Pacific dominated the global market ... private sectors. Continue Reading ... ...
Breaking Biology News(10 mins):